NASDAQ · Biotechnology

Kazia Therapeutics Ltd ADR (KZIA) Stock

$14.54 +2.76% NASDAQ: KZIA Healthcare

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Valuation

MetricValue
Price$14.54
Market Cap$23.55M
P/E Ratio-2.01
P/B Ratio1.40
P/S Ratio1707.89
EPS (TTM)$-18.90
52-Week High$17.40
52-Week Low$4.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-116.86%
ROA-31.35%
ROCE-38.87%
Gross Margin100.00%
Operating Margin-14641.04%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.87

Annual Financials (USD)

Metric20212022202320242025
Revenue$15.0M$0$0$2.0M$0
Operating Profit$-6.0M$-25.0M$-24.0M$-28.0M$-14.0M
Net Profit$-8.0M$-25.0M$-20.0M$-27.0M$-21.0M
EPS$-35.80$-95.00$-55.00$-55.00$-18.90
Op Margin-42.0%-253990.0%-4346661.1%-1233.2%-33850.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$36.0M$28.0M$22.0M$6.0M
Total Liabilities$20.0M$18.0M$16.0M$32.0M$14.0M
Cash$28.0M$7.0M$5.0M$2.0M$4.0M
Borrowings$0$2.0M$2.0M$1.0M$0

Latest News

Kazia Therapeutics Appoints James Levine as Chief Financial Officer PR Newswire · Jun 2, 2026 Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire · May 26, 2026 How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform Insider Monkey · Apr 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-23.0M$-15.0M$-10.0M$-13.0M
Investing Cash Flow$0$-2.0M$0$0$0
Financing Cash Flow$28.0M$0$13.0M$0$1.0M
Net Cash Flow$19.0M$-20.0M$-2.0M$-4.0M$3.0M
Free Cash Flow$-9.0M$-23.0M$-15.0M$-10.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA1.96
FCF Yield-26.96%
Quick Ratio2.87
Interest Coverage0.00
Return 1Y47.46%
Return 3Y-66.19%
Return 5Y-97.01%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BDRXBiodexa Pharmaceuticals Plc $1.71 -3.39% 0.00 $1.28M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CMND $1.62 +0.52% -0.79 $2.41M 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%
GRI $1.46 -5.81% -0.33 $131155 0.00%

About Kazia Therapeutics Ltd ADR

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics Ltd ADR is headquartered in AU.

Kazia Therapeutics Ltd ADR (KZIA) stock trades at $14.54 with a market capitalization of $23.55M. The stock is valued at a price-to-earnings (P/E) ratio of -2.01, price-to-book of 1.40, price-to-sales of 1707.89. Over the past 52 weeks the stock has ranged between $4.86 and $17.40, and currently trades 16.4% below its 52-week high.

On profitability, Kazia Therapeutics Ltd ADR generates a return on equity (ROE) of -116.86%, return on capital employed of -38.87%, an operating margin of -14641.04%, a net profit margin of 0.00%.

Official website: www.kaziatherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides